White-Label HRT Brand: How to Launch a Hormone Therapy Telehealth Company

To launch a white-label HRT brand, you build the company and a platform supplies the clinical and operational infrastructure: branded patient signup, licensed Providers, a compounding pharmacy, and compliance. You choose the name, own the patient relationship, and keep the revenue above costs. This guide walks through each part of the launch.

Hormone replacement therapy is one of the most underserved and fastest-growing categories in cash-pay telehealth. Millions of women in perimenopause and menopause are actively seeking treatment, the clinical evidence for HRT has dramatically improved over the past decade, and a generation of direct-to-consumer brands has demonstrated strong demand for accessible, subscription-based programs.

For Entrepreneurs, Creators, and Clinic Owners, this creates a substantial opportunity: a large addressable market, a recurring-revenue business model, and a patient population with long retention and high lifetime value.

This guide covers everything you need to understand before launching your own HRT brand: the market opportunity, how compounded bioidentical hormones work, how the business model functions, what you need to get started, the economics, and the regulatory landscape you need to operate within.

What Is a White-Label HRT Brand?

A white-label HRT brand is a company you own, named after your business, that runs on infrastructure supplied by a platform. Patients never see the platform’s name. They see your name on the website, the signup, their communications, and their ongoing care.

What you own:

• The brand and the patient list. The company name, domain, marketing assets, and every patient relationship. A patient who stays two years is your asset, not the platform’s.
• Pricing and margin. You set patient pricing. Your margin is the difference between what patients pay and what you pay for medication, Provider consults, and a monthly platform fee.
• Exit value. A white-label company with a stable patient list has transferable value. A referral arrangement where someone else owns the patients does not.

What the platform supplies:

• Branded patient signup tailored to HRT, with symptom and medical history collection
• Eligibility screening that catches contraindications before a Provider review
• Licensed Providers from a 50-state network, or support for your own Provider
• Compounding pharmacy integration and fulfillment that ships medication to patients
• HIPAA-compliant records, payment processing, and compliance infrastructure

This is the ownership model behind the large cash-pay hormone companies operating today. The operator keeps the patient relationship, the data, and the margin; the platform stays invisible. To see the platform layer in practice, Karpa’s white-label HRT and women’s health platform shows how the pieces fit together.

The HRT Market Opportunity

The scale of unmet demand for hormone therapy is significant.

Approximately 1.3 million women in the United States enter menopause every year, according to data from the North American Menopause Society. The perimenopausal transition typically begins in the mid-40s, meaning the total addressable population of symptomatic women is in the tens of millions at any given time.

Despite this scale, most women receive no treatment. A combination of factors created an enormous gap:

• The 2002 Women’s Health Initiative study generated significant controversy about HRT safety and led to a steep decline in prescribing that lasted nearly two decades
• Primary care physicians spend an average of less than 2 hours on menopause education during medical school and residency, according to research published in Menopause
• Insurance coverage for hormone therapy is inconsistent and many patients prefer cash-pay for privacy and simplicity

The result is a large, motivated patient population with disposable income actively searching for competent providers willing to prescribe modern HRT protocols. Telehealth brands like Alloy, MIDI Health, Evernow, and Caria have demonstrated that this population converts well through digital channels.

The clinical narrative has also shifted. Comprehensive reviews and the NAMS 2022 Hormone Therapy Position Statement now affirm that HRT benefits outweigh risks for most healthy women under 60 who are within 10 years of menopause onset. This evidence base makes HRT easier to discuss, prescribe, and market appropriately.

For a white-label operator, this market is reachable without building any clinical infrastructure. You bring the brand and the marketing; the platform brings the prescribing and the fulfillment. That division of labor is the entire premise of the white-label model.

Understanding Compounded Bioidentical Hormones

What Bioidentical Means

Bioidentical hormones are identical in molecular structure to the hormones naturally produced by the human body. The most clinically relevant distinction is between bioidentical progesterone and synthetic progestins like medroxyprogesterone acetate (MPA), which differ in molecular structure and have different receptor binding profiles.

Compounded bioidentical HRT uses pharmaceutical-grade APIs manufactured by licensed compounding pharmacies. The formulations are not FDA-approved finished drug products, but the underlying molecules (estradiol, progesterone, testosterone) are well-characterized and widely used in both compounded and FDA-approved form.

Common Medications in HRT Programs

Estradiol (Estrogen)

Estradiol is the primary estrogen used in HRT programs. It is available in multiple delivery methods, each with distinct pharmacokinetics and patient preferences:

• Transdermal cream or gel: Applied daily to thin-skinned areas (inner arm, inner thigh). Compounded at custom strengths. Avoids first-pass liver metabolism, which is clinically relevant for cardiovascular risk.
• Sublingual troche: Placed under the tongue for rapid absorption. Popular with patients who prefer not to apply cream.
• Oral capsule: Convenient but undergoes first-pass metabolism; requires higher doses for equivalent systemic effect.
• Vaginal formulations: Low-dose estriol or estradiol used specifically for genitourinary symptoms without significant systemic absorption.

Progesterone

Progesterone is prescribed alongside estradiol for women with an intact uterus to protect the endometrium. Compounded bioidentical progesterone is functionally equivalent to FDA-approved oral progesterone (Prometrium) and is available as:

• Oral capsule: Most common. Taken at bedtime due to sedating effect.
• Transdermal cream: Lower systemic absorption than oral; sometimes used for women with digestive sensitivity.
• Sublingual troche: Higher systemic absorption than cream.

Testosterone for Women

Low-dose testosterone is increasingly incorporated into women’s HRT protocols to address libido, energy, cognitive function, and mood. Compounded at doses approximately 10x lower than male TRT programs:

• Transdermal cream: Typical compounded concentration 1% to 2%, applied to inner thigh or labia.
• Sublingual troche: Alternative delivery for patients who prefer not to apply cream.

DHEA and Estriol

DHEA (dehydroepiandrosterone) is sometimes added to support adrenal hormone production. Estriol, a weak estrogen, is used in vaginal formulations and in some practitioners’ systemic protocols.

Compounded vs FDA-Approved HRT

Compounded HRT is the commercial backbone of most cash-pay HRT programs because it allows custom dosing and delivery methods, at a price point that works for patients, with the flexibility to adjust formulations as patients are optimized. White-label brands standardize on compounded formulations because the model gives them control: their own protocols, their own tier structure, and a patient experience they define.

Who Your Patients Are

Understanding the patient population shapes everything from marketing to protocol design. Every segment below maps to a specific acquisition channel and a specific retention profile for your brand.

The Perimenopausal Patient

Perimenopause typically begins in the mid to late 40s and can last 4 to 8 years. Symptoms include irregular cycles, hot flashes, night sweats, sleep disruption, mood changes, brain fog, weight gain, and decreased libido. Many perimenopausal women have normal or only slightly irregular hormone levels on testing, which makes diagnosis clinical rather than purely lab-based.

This patient is often frustrated by primary care providers who attribute symptoms to stress or aging. She has done her own research, knows what she wants, and is willing to pay cash.

The Postmenopausal Patient

Postmenopause begins 12 months after the final period. Estrogen levels have dropped substantially. Symptoms include persistent vasomotor symptoms, vaginal dryness, joint pain, cardiovascular risk changes, and bone density loss. These patients have clear lab findings that support HRT and are often the highest-retention cohort because their need for therapy is definitive.

The Surgical Menopause Patient

Women who have undergone oophorectomy experience immediate surgical menopause, often at younger ages than natural menopause. This population has the strongest clinical indication for HRT and the longest potential treatment duration.

Marketing Channels That Work

HRT patients are reachable through:

• Meta advertising: Women 40-60 respond well to symptom-focused creative and educational content
• Organic search and content: High-volume searches for “perimenopause symptoms,” “bioidentical hormones,” and “HRT telehealth” represent bottom-of-funnel intent
• Podcast advertising: Health and wellness podcasts with female audiences in the 40s-50s demographic convert well
• Influencer partnerships: Female health and longevity creators with audiences in the perimenopause demographic can drive qualified patient referrals

Every channel funnels to your branded signup page, which is where the white-label model earns its keep: the patient converts on your site, under your name, into your company.

The Business Model: How a White-Label HRT Brand Makes Money

An HRT telehealth brand is a subscription healthcare business. Revenue flows from monthly program fees paid by patients on ongoing therapy.

The basic model:

1. Patient acquisition through digital advertising, SEO, referrals, or existing practice relationships
2. Patient signup: The patient completes a health history questionnaire, symptom assessment, and lab review
3. Provider Review: A licensed Provider evaluates the patient’s signup and medical history and, if appropriate, issues a prescription for an individualized HRT protocol
4. Pharmacy fulfillment: A compounding pharmacy prepares the customized formulation and ships directly to the patient
5. Monthly subscription: The patient pays a recurring fee that covers the medication, Provider access, and ongoing management
6. Renewal and monitoring: Labs are repeated at intervals; the Provider adjusts the protocol as needed; the patient remains on a monthly subscription

In a white-label structure, all of this revenue flows to your company. You set the program price, and your margin is the difference between what patients pay and what you pay for medication, Provider consults, and a monthly platform fee. The platform is a cost center on your P&L, not a partner taking a cut of your patients.

Optional Revenue Layers for a White-Label Brand

White-label HRT brands can add revenue through:

• Comprehensive hormone panels: Initial and follow-up lab panels charged at cash-pay rates or included in premium tiers
• On-demand provider messaging: Patients pay for asynchronous provider access beyond standard check-ins
• Pellet therapy: Testosterone and estradiol pellets implanted subcutaneously every 3 to 6 months. Premium-priced ($400 to $800 per insertion visit) and in-person delivery only. Strong add-on for Clinic Owners with physical locations.
• Complementary programs: HRT patients are excellent candidates for GLP-1 weight loss, peptide therapy, and skin care programs
• Supplement subscriptions: Magnesium, collagen, adaptogens, and other supplements commonly used alongside HRT

Each add-on raises revenue per patient without proportional acquisition cost. That compounding effect is what separates a strong white-label brand from a single-product operation.

What You Need to Launch a White-Label HRT Brand

Four core components are required to operate an HRT telehealth company. None require a medical license.

1. A Clinical Platform

You need software to manage patient signup, eligibility screening, Provider workflows, prescription routing, and ongoing communication. Building this from scratch means hiring developers, negotiating pharmacy APIs, and staying current on compliance, which is why most operators use a white-label platform instead.

A white-label platform comes pre-built with HRT-specific signup questionnaires, clinical decision support, and pharmacy integrations, all rendered under your domain and brand. When evaluating platforms, compare four things: whether every patient-facing page carries your brand, whether the HRT-specific workflows are built in, which compounding pharmacies are integrated, and whether the provider model covers the states you want to serve. For a feature-by-feature comparison, read our guide to the best software for BHRT clinics and our walkthrough of how to evaluate HRT clinic software for compounding pharmacy integration.

2. A Prescribing Network

Every prescription must be issued by a licensed Provider. If you are not a clinician, you need access to a prescribing network covering all states where you plan to serve patients. White-label platforms typically include access to a 50-state Provider Network as part of the monthly platform fee, which removes geographic limitations entirely. If you are a licensed practice, you can also bring your own Provider and keep prescribing authority in-house.

3. A Compounding Pharmacy Partner

Your pharmacy partner prepares patient-specific hormone formulations and ships directly to patients. Key criteria for HRT pharmacy partners:

• PCAB (Pharmacy Compounding Accreditation Board) accreditation is a strong quality signal
• Third-party potency and sterility testing with certificates of analysis available
• Experience with hormone formulations specifically (not all compounding pharmacies specialize in this)
• Direct-to-patient shipping with appropriate temperature controls
• Licensed in the states where your patients are located

4. A Patient Acquisition Strategy

Acquisition is the one part of the business a white-label operator is fully responsible for. Paid digital advertising is the primary channel for most HRT brands. HRT patients search actively for solutions, which means SEO and content marketing also deliver qualified leads at lower cost than paid. Referral programs and influencer partnerships add acquisition volume without proportional cost increases.

Brand assets matter here. A name, a domain, and a consistent visual identity make paid campaigns convert better, and they are what patients remember when they refer a friend. The platform handles the back end; the brand is what wins the patient.

Economics: Revenue Model and Patient LTV

Sample Program Economics

Assume a program price of $220 per month for a standard HRT subscription (estradiol plus progesterone, compounded, with provider access and annual lab review).

At a monthly churn rate of 4% (HRT patients are highly retained once stabilized), average patient lifetime is approximately 25 months. At $220 per month, average patient lifetime value is approximately $5,500.

If you are acquiring patients at $180 per patient, your payback period is under one month and your return on acquisition spend is over 30x over the patient lifetime.

Scale Economics

These projections assume a single $220/month plan with 4% monthly churn. Real programs have plan tiers, higher-priced add-ons, and varying churn rates. The core dynamic holds: HRT is a high-retention, recurring-revenue model where scale compounds quickly.

Because a white-label operator sets patient pricing, these revenue figures are yours to design. Your cost side is the platform fee, medication, and Provider consult costs; everything above that is margin. Tiers and add-ons push revenue per patient up without moving acquisition cost.

Key Metrics to Track

• Monthly Recurring Revenue (MRR): Total active subscriptions per month
• Patient Acquisition Cost (PAC): Total marketing spend divided by new patients acquired
• Monthly Churn Rate: Percentage of active patients who cancel each month
• Patient Lifetime Value (LTV): Average revenue per patient over their full retention period
• LTV:PAC Ratio: Target 3:1 or higher for a sustainable program

Regulatory Landscape

FDA and Compounding Pharmacy Rules

Compounded bioidentical HRT operates primarily under Section 503A of the Federal Food, Drug, and Cosmetic Act. Unlike compounded GLP-1 medications, which are tied to drug shortage status, compounded hormones in custom formulations are not generally considered copies of specific FDA-approved products. This gives compounded HRT a more stable legal footing.

The FDA has published guidance on bulk drug substances used in compounding. Estradiol, progesterone, and testosterone are well-established APIs with long regulatory histories. Work with pharmacies that maintain current compliance documentation and can demonstrate their quality testing practices.

Telehealth Prescribing

HRT prescriptions can be issued via telehealth in most states. Unlike testosterone in male TRT programs (a Schedule III controlled substance), estradiol and progesterone are not controlled substances, which simplifies telehealth prescribing significantly. However, state-specific telehealth consent requirements and prescribing restrictions vary. Your prescribing network should maintain current state-by-state compliance documentation.

HIPAA Compliance

Any platform processing patient health information must comply with HIPAA. This includes signup forms, communication tools, lab result workflows, and any advertising pixels on patient-facing pages. Ensure Business Associate Agreements are in place with all technology and pharmacy partners, and in a white-label arrangement confirm that the platform, the pharmacy, and any lab partner all execute BAAs with your company. For a deeper review of HIPAA requirements in cash-pay programs, read our HIPAA compliance guide for cash-pay medication programs.

Advertising and Health Claims

The FTC regulates health claims in advertising. For HRT brands, avoid unsubstantiated outcome promises and ensure all efficacy claims are grounded in peer-reviewed evidence. Reference organizations like NAMS or the Endocrine Society when citing clinical support for HRT. Review the FTC’s health products compliance guidance before running paid campaigns.

How to Build for Retention

HRT brands live or die on patient retention. The clinical evidence strongly supports long-term therapy, which means the primary retention driver is patient experience, not clinical need. For a white-label operator, retention is where brand ownership pays off: the patients you keep are your asset, not the platform’s.

High-retention HRT brands consistently do three things:

1. Set expectations before symptoms resolve. Patients starting HRT often expect rapid relief. Transdermal estradiol takes 2 to 4 weeks to achieve steady-state levels. Patients who are not prepared for this timeline sometimes cancel before experiencing benefit. Clear onboarding communication reduces this early dropout window significantly.

2. Offer protocol adjustability. Hormone optimization is not a one-size-fits-all process. Patients who feel unheard when their initial protocol is not working will leave. Programs with proactive check-ins at 4 to 6 weeks and a clear process for requesting dose adjustments retain patients at dramatically higher rates.

3. Build the multi-program relationship. HRT patients over 40 frequently have concurrent health goals: weight management, skin health, energy, cognitive performance. Programs that introduce complementary offerings (peptides, GLP-1, compounded skincare) over time increase revenue per patient and deepen the relationship, making cancellation less likely. For operators also serving male patients, the process for adding a TRT program to your clinic follows the same playbook.

Launch Checklist

Use this checklist to track your white-label HRT brand launch:

1. Choose your brand name and domain, and define your program scope (which hormones, delivery methods, tier structure)
2. Confirm Provider coverage (own Provider or Provider Network)
3. Select and contract with a compounding pharmacy specializing in hormone formulations
4. Set up patient signup forms specific to HRT (symptom assessment, medical history, contraindications)
5. Establish lab ordering workflow (patient-directed or integrated)
6. Create informed consent documentation
7. Set pricing and program tiers under your brand’s name
8. Build HIPAA-compliant patient communication workflows
9. Define onboarding protocol (initial consult, 4-week check-in, 3-month follow-up)
10. Launch patient acquisition campaigns targeting perimenopausal and postmenopausal demographics

How Karpa Health Helps You Launch

Karpa Health provides the complete infrastructure for launching and scaling a white-label HRT brand. The Platform includes white-label patient signup, a 50-state Provider Network, integrated Pharmacy Integration, Fulfillment, and the practice management tools needed to run a compliant, scalable company.

You bring the brand name, the patients, and the business. Karpa provides the clinical and operational backbone, and patients never see Karpa’s name anywhere in your funnel. It is your company, your pricing, and your patient relationships, running on infrastructure you did not have to build.

If you are ready to launch your own HRT brand, book a call with Karpa Health to map out the launch.